Hyperprogression after one dose of nivolumab in sinonasal cancer: A case report
| Autor: | Jenny Jing Xiang, Barbara Burtness, Frank J. Minja, Erol Verter, Natalie Uy |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty business.industry Immune checkpoint inhibitors medicine.medical_treatment Head and neck cancer Immunotherapy Disease Sinonasal cancer medicine.disease Head and neck squamous-cell carcinoma 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Otorhinolaryngology 030220 oncology & carcinogenesis Internal medicine medicine Maxillary Sinus Squamous Cell Carcinoma Nivolumab business |
| Zdroj: | The Laryngoscope. 130:907-910 |
| ISSN: | 1531-4995 0023-852X |
| DOI: | 10.1002/lary.28042 |
| Popis: | In head and neck squamous cell carcinoma, immune checkpoint inhibitors (ICI) lead to improved outcomes. There has been reports of accelerated disease progression, or hyperprogression, after ICI initiation. We present a case of hyperprogression after one dose of nivolumab in maxillary sinus squamous cell carcinoma. The patient had complete vision loss due to disease progression into the orbit, as well as intracranial invasion, lytic metastases, and new widespread distal metastases. Hyperprogression can occur after the first dose of immunotherapy. Absent biomarkers regarding individual risk of hyperprogression, caution should be exercised in using ICI in sinonasal cancers with orbital abutting disease. Laryngoscope, 130:907-910, 2020. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text